In this article, we describe the study protocol of MONARCC, a randomised phase II study of panitumumab monotherapy and panitumumab plus 5-FU as first-line therapy for RAS and BRAF wildtype metastatic colorectal cancer. Here, BRAF is linked to metastatic colorectal cancer.